Abstract
Palmitoylethanolamide (PEA) is one of a class of naturally occurring lipidic molecules composed of a fatty acid and ethanolamine, namely the fatty acid ethanolamides (FAEs). PEA is abundant in mammalian brain and, for other FAEs, is produced through an ondemand synthesis within the lipid bilayer [1]. The potential benefit of FAEs was first recognized in the early 1940s with the reported antipyretic properties of dried chicken egg yolk in children with rheumatic fever [2]. A decade later, the lipid fraction from egg yolk was identified as the component responsible for this effect [3], with PEA being the active component [4]. The potential applications of this lipid amide remained largely overlooked, however, until the characterization of its anti-inflammatory [5], analgesic [6], and anticonvulsant [7] properties. Indeed, these past 15 years have seen a noteworthy increase in studies dealing with the antiinflammatory actions of PEA [8]. Such was the impetus behind an international conference held in Pozzuoli 9-10 February 2012 and the first ever dedicated to this fast-growing area of biomedical research.....
CNS & Neurological Disorders - Drug Targets
Title:Conference Report
Volume: 11 Issue: 3
Author(s): Stephen D. Skaper
Affiliation:
Abstract: Palmitoylethanolamide (PEA) is one of a class of naturally occurring lipidic molecules composed of a fatty acid and ethanolamine, namely the fatty acid ethanolamides (FAEs). PEA is abundant in mammalian brain and, for other FAEs, is produced through an ondemand synthesis within the lipid bilayer [1]. The potential benefit of FAEs was first recognized in the early 1940s with the reported antipyretic properties of dried chicken egg yolk in children with rheumatic fever [2]. A decade later, the lipid fraction from egg yolk was identified as the component responsible for this effect [3], with PEA being the active component [4]. The potential applications of this lipid amide remained largely overlooked, however, until the characterization of its anti-inflammatory [5], analgesic [6], and anticonvulsant [7] properties. Indeed, these past 15 years have seen a noteworthy increase in studies dealing with the antiinflammatory actions of PEA [8]. Such was the impetus behind an international conference held in Pozzuoli 9-10 February 2012 and the first ever dedicated to this fast-growing area of biomedical research.....
Export Options
About this article
Cite this article as:
D. Skaper Stephen, Conference Report, CNS & Neurological Disorders - Drug Targets 2012; 11 (3) . https://dx.doi.org/10.2174/187152712800672427
DOI https://dx.doi.org/10.2174/187152712800672427 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Patents of Complementary and Alternative Medicine for Allergic Rhinitis
Recent Patents on Inflammation & Allergy Drug Discovery The Role of Aryl Hydrocarbon Receptor-Regulated Cytochrome P450 Enzymes in Glioma
Current Pharmaceutical Design Biochemical Markers for Brain Injury Monitoring in Children with or without Congenital Heart Diseases
CNS & Neurological Disorders - Drug Targets Post-Translational Modifications of PTEN and their Potential Therapeutic Implications
Current Cancer Drug Targets Dual Inhibitors of Monoamine Oxidase and Cholinesterase for the Treatment of Alzheimer Disease
Current Topics in Medicinal Chemistry Perinatal Brain Injury
Current Pediatric Reviews A Comprehensive Review of Pharmacokinetics and Pharmacodynamics in Animals: Exploration of Interaction with Antibiotics of Shuang-Huang- Lian Preparations
Current Topics in Medicinal Chemistry Recent Progress in Mutation-driven Therapy, Immunotherapy and Combination Therapy for the Treatment of Melanoma
Current Cancer Drug Targets Adult Stem Cells and Bioengineering Strategies for the Treatment of Cerebral Ischemic Stroke
Current Stem Cell Research & Therapy Commentary: Functional Neuronal CB2 Cannabinoid Receptors in the CNS
Current Neuropharmacology Current Status of Thalidomide and CC-5013 in the Treatment of Metastatic Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Endogenous Events Modulating Myogenic Regulation of Cerebrovascular Function
Current Vascular Pharmacology Activation of Latent HIV-1 Expression by Protein Kinase C Agonists. A Novel Therapeutic Approach to Eradicate HIV-1 Reservoirs
Current Drug Targets Inhibitors of Endocannabinoid Degradation as Potential Therapeutic Agents: An Update
Medicinal Chemistry Reviews - Online (Discontinued) Prodrugs of Non-steroidal Anti-inflammatory Drugs (NSAIDs): A Long March Towards Synthesis of Safer NSAIDs
Mini-Reviews in Medicinal Chemistry Senescence of the Brain: Focus on Cognitive Kinases
Current Pharmaceutical Design <i>Nigella sativa</i> – A Functional Spice From A Pharaoh’s Tomb to Modern Healthcare
The Natural Products Journal The Atypical Cannabinoid O-1602: Targets, Actions, and the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Chemokines and Brain Functions
Current Drug Targets - Inflammation & Allergy Calcium Sensitizers in Cardiac Surgery: Who, When, How and Why?
Current Vascular Pharmacology